Soleno Therapeutics Inc (NASDAQ:SLNO) finished Thursday with an addition of $6.92 to close at $27.59, an upside of 33.48 percent. An average of 11,402,420 shares of common stock have been traded in the last five days. There was a gain of $23.48 in the past week, and it reached a new high 23 times over the past 12 months. The last 20 days have seen an average of 2,935,480 shares traded, while the 50-day average volume stands at 1,202,030.
SLNO stock has increased by 413.78% in the last month. The company shares reached their 1-month lowest point of $3.69 on 09/07/23. With the stock rallying to its 52-week high on 09/26/23, shares of the company touched a low of $0.85 and a high of $30.30 in 52 weeks. It has reached a new high 19 times so far this year and achieved 1293.43% or $25.61 in price. In spite of this, the price is down -8.94% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
SLNO stock investors should be aware that Soleno Therapeutics Inc (SLNO) stock had its last reported insider trading activity 294 days ago on Sep 28. In this transaction, the insider spent $9,100. 10% Owner, SCHULER JACK W, disposed of 10,000 shares at a price of $0.93 on Dec 08. The insider now owns more than $9,300 worth of shares. Prior to that, 10% Owner SCHULER JACK W went on to Sale 10,000 shares at $0.96 each on Dec 07. An amount of $9,600 was transacted.
Valuation Metrics
Soleno Therapeutics Inc (SLNO) stock’s beta is -0.94. Other valuation ratios to consider include the price-to-book (PB) ratio at 20.30.
Financial Health
The quick ratio of Soleno Therapeutics Inc for the three months ended June 29 was 2.33, and the current ratio was 2.33, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.02 and a total debt to equity ratio of 0.04 for the quarter ending June 29. Its gross profit as reported stood at $0.33 million compared to revenue of $24.4 million.
Earnings Surprise
The company posted a net income of -$8.48 million in the quarter, while revenues of -$8.36 million were grew 20.64%. The analyst consensus anticipated Soleno Therapeutics Inc’s latest quarter earnings to come in at -$0.83 per share, but it turned out to be -$0.81, a 2.40% surprise. Shareholders own equity worth $9.99 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Soleno Therapeutics Inc (SLNO) price momentum. RSI 9-day as of the close on 28 September was 80.56%, suggesting the stock is Overbought, with historical volatility in this time frame at 914.39%.
As of today, SLNO’s price is $16.75 +571.29% or $23.48 from its 5-day moving average. SLNO is currently trading +439.92% higher than its 20-day SMA and +611.08% higher than its 100-day SMA. However, the stock’s current price level is +434.69% above the SMA50 and +2,964.87% above the SMA200.
The stochastic %K and %D were 80.13% and 69.52%, respectively, and the average true range (ATR) was 4.07. With the 14-day stochastic at 89.77% and the average true range at 2.91, the RSI (14) stands at 79.93%. The stock has reached 13.77 on the 9-day MACD Oscillator while the 14-day reading was at 16.27.
Analyst Ratings
Guggenheim launched coverage on Soleno Therapeutics Inc (NASDAQ: SLNO) in its analyst report released on September 29, 2020. The firm assigned the stock a Buy rating. The consensus rating for Soleno Therapeutics Inc (SLNO) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell SLNO, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 3 others rate it as a “buy”.
What is SLNO’s price target for the next 12 months?
Analysts predict a range of price targets between $35.00 and $39.00, with a median target of $39.00. Taking a look at these predictions, the average price target given by analysts for Soleno Therapeutics Inc (SLNO) stock is $37.67.
